Omapatrilat is a novel antihypertensive agent that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling. This drug from Bristol-Myers Squibb was not approved by the U.S. Food and Drug Administration due to angioedema safety concerns.
| Property | Value |
|---|
| dbpprop:abstract
|
- Omapatrilat is a novel antihypertensive agent that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling. This drug from Bristol-Myers Squibb was not approved by the U.S. Food and Drug Administration due to angioedema safety concerns.
|
| dbpprop:hasPhotoCollection
| |
| rdf:type
| |
| rdfs:comment
|
- Omapatrilat is a novel antihypertensive agent that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling. This drug from Bristol-Myers Squibb was not approved by the U.S. Food and Drug Administration due to angioedema safety concerns.
|
| rdfs:label
| |
| owl:sameAs
| |
| skos:subject
| |
| foaf:page
| |
| is owl:sameAs
of | |
![[RDF Data]](/statics/sw-cube.png)
